Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Preferred Stock Liabilities: 2023

Historic Preferred Stock Liabilities for Contineum Therapeutics (CTNM) over the last 1 years, with Dec 2023 value amounting to $192.6 million.

  • Contineum Therapeutics' Preferred Stock Liabilities was N/A to $192.6 million in Q1 2024 from the same period last year, while for Mar 2024 it was $192.6 million, marking a year-over-year change of. This contributed to the annual value of $192.6 million for FY2023, which is N/A change from last year.
  • Per Contineum Therapeutics' latest filing, its Preferred Stock Liabilities stood at $192.6 million for FY2023.
  • Contineum Therapeutics' Preferred Stock Liabilities' 5-year high stood at $192.6 million during FY2023, with a 5-year trough of $192.6 million in FY2023.
  • Over the past 1 years, Contineum Therapeutics' median Preferred Stock Liabilities value was $192.6 million (recorded in 2023), while the average stood at $192.6 million.